Yale School of Medicine Welcomes First-year MD and MD-PhD Students
The students comprising the incoming Yale School of Medicine (YSM) MD class of 2024 experienced an unconventional recruitment process due to COVID-19, but YSM Director of Admissions Ayaska Fernando says he is thrilled with the exceptional group who have chosen to attend the school.
YSM Team Proposes a Novel Approach to Addressing Racism in Medical Education
“Most medical schools are white spaces where explicit and implicit racism occurs constantly and often goes unmentioned and unpunished,” according to a recently published article. Authored by Yale School of Medicine (YSM) Psychiatry Resident Nientara Anderson, MHS, MD; Dowin Boatright, MD, MBA, MHS, assistant professor of emergency medicine; and Anna Reisman, MD, professor and director, Program for Humanities in Medicine, Blackface in White Space: Using Admissions to Address Racism in Medical Education, appeared in the Journal of General Internal Medicine.
In Conversation: Volkmar on Supporting Children with Developmental Disorders During COVID-19
Departure from routine can be especially hard for children with developmental disorders, and the changes to daily life wrought by the pandemic pose an extra challenge for them and for their families.Source: YaleNews
Yale Named Top Ten Center of Biomedical Research by The Hartwell Foundation
As a Top Ten Center, Yale will have the opportunity to submit an increased number of applications to The Hartwell Foundation’s Individual Biomedical Research Award program, which supports early-stage, innovative, and cutting-edge biomedical research with the potential to benefit children in the U.S.
Blocking a ‘Jamming Signal’ Can Unleash Immune System to Fight Tumors
Yale researchers have discovered a “jamming signal” that blocks a powerful immune system stimulant called interleukin-18 (IL-18) from reaching tumors, including in cancers that are resistant to conventional immunotherapy treatments, they report June 24 in the journal Nature.
Yale's Human Genomics Efforts Get a New Boost
Under its incoming director, Ira M. Hall, PhD, the Yale Center for Genomic Health will have goals that include creating and leading studies of human genome variation and disease; enhancing the university’s abilities in computational genomics, bioinformatics, and data science; and leading efforts at Yale to implement genomics in health care.
Yale and NBA Partner to Study Efficacy of New COVID-19 Test
A research team led by Yale’s Nathan Grubaugh and Anne Wyllie will begin testing select players, coaches, and staff from the NBA teams that have opted into the study, using a testing method they developed, known as SalivaDirect. The results of the study are expected by the end of July and will be shared publicly.Source: YaleNews
Carefully, Yale Labs Stir to Life Across Campus
Since June 1, the start of a broad, three-phase reactivation of campus, an estimated 4,000 faculty members, graduate students, and staff representing more than 500 labs around Yale have fired up microscopes, opened fume hoods, or dusted off other essential research equipment.Source: YaleNews
Blood Protein Predicts Poor COVID-19 Outcomes
Low levels of the blood protein renalase predict poor outcomes in patients with COVID-19, Yale researchers report. They are planning to ask for expedited approval from the U.S. Food and Drug Administration to investigate whether the protein, which fights inflammation, might improve outcomes of patients with severe cases of the disease.Source: YaleNews
Public Health Professor Plays Key Role as Connecticut Recovers from Pandemic
To Connecticut Gov. Ned Lamont, Yale School of Public Health Professor Albert Ko is “our Dr. Fauci.” Much like the actual Dr. Tony Fauci, director of National Institute of Allergy and Infectious Diseases and a familiar national presence throughout the pandemic, Ko takes the ongoing fight against COVID-19 extremely seriously. Though cases are in decline since rates of disease peaked in late April, and the state is seeing a decrease of hospitalizations and deaths, to Ko, the fight has just begun.
Yale Cancer Center Study Shows Profound Benefit with Targeted Therapy for Patients with Early Stage NSCLC
According to findings led by researchers at Yale Cancer Center, treatment with the targeted therapy osimertinib following surgery significantly improves disease-free survival (DFS) in patients with early-stage, non-small cell lung cancer (NSCLC) with EGFR gene mutations.